259 related articles for article (PubMed ID: 28904063)
1. Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.
Sierra RA; Trillo-Tinoco J; Mohamed E; Yu L; Achyut BR; Arbab A; Bradford JW; Osborne BA; Miele L; Rodriguez PC
Cancer Res; 2017 Oct; 77(20):5628-5638. PubMed ID: 28904063
[TBL] [Abstract][Full Text] [Related]
2. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.
Mohamed E; Sierra RA; Trillo-Tinoco J; Cao Y; Innamarato P; Payne KK; de Mingo Pulido A; Mandula J; Zhang S; Thevenot P; Biswas S; Abdalla SK; Costich TL; Hänggi K; Anadon CM; Flores ER; Haura EB; Mehrotra S; Pilon-Thomas S; Ruffell B; Munn DH; Cubillos-Ruiz JR; Conejo-Garcia JR; Rodriguez PC
Immunity; 2020 Apr; 52(4):668-682.e7. PubMed ID: 32294407
[TBL] [Abstract][Full Text] [Related]
3. T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy.
Raber PL; Sierra RA; Thevenot PT; Shuzhong Z; Wyczechowska DD; Kumai T; Celis E; Rodriguez PC
Oncotarget; 2016 Apr; 7(14):17565-78. PubMed ID: 27007050
[TBL] [Abstract][Full Text] [Related]
4. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
5. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
6. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
[TBL] [Abstract][Full Text] [Related]
7. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
8. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy.
Lan J; Li R; Yin LM; Deng L; Gui J; Chen BQ; Zhou L; Meng MB; Huang QR; Mo XM; Wei YQ; Lu B; Dicker A; Xue JX; Lu Y
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):74-87. PubMed ID: 29619980
[TBL] [Abstract][Full Text] [Related]
9. AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.
Trillo-Tinoco J; Sierra RA; Mohamed E; Cao Y; de Mingo-Pulido Á; Gilvary DL; Anadon CM; Costich TL; Wei S; Flores ER; Ruffell B; Conejo-Garcia JR; Rodriguez PC
Cancer Res; 2019 Oct; 79(19):5034-5047. PubMed ID: 31409640
[TBL] [Abstract][Full Text] [Related]
10. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
[TBL] [Abstract][Full Text] [Related]
11. The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.
Luker AJ; Graham LJ; Smith TM; Camarena C; Zellner MP; Gilmer JS; Damle SR; Conrad DH; Bear HD; Martin RK
BMC Immunol; 2020 Feb; 21(1):8. PubMed ID: 32106810
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
13. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.
Jeanbart L; Kourtis IC; van der Vlies AJ; Swartz MA; Hubbell JA
Cancer Immunol Immunother; 2015 Aug; 64(8):1033-46. PubMed ID: 25982370
[TBL] [Abstract][Full Text] [Related]
14. Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model.
Adah D; Yang Y; Liu Q; Gadidasu K; Tao Z; Yu S; Dai L; Li X; Zhao S; Qin L; Qin L; Chen X
Cell Commun Signal; 2019 Apr; 17(1):32. PubMed ID: 30979375
[TBL] [Abstract][Full Text] [Related]
15. Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T-cell proliferation.
Bian Z; Abdelaal AM; Shi L; Liang H; Xiong L; Kidder K; Venkataramani M; Culpepper C; Zen K; Liu Y
Eur J Immunol; 2018 Jun; 48(6):1046-1058. PubMed ID: 29488625
[TBL] [Abstract][Full Text] [Related]
16. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model.
Hu Y; Liu J; Cui P; Liu T; Piao C; Xu X; Zhang Q; Xiao M; Lu Y; Liu X; Wang Y; Lu X
Cell Immunol; 2020 Feb; 348():104036. PubMed ID: 31924315
[TBL] [Abstract][Full Text] [Related]
18. Curdlan blocks the immune suppression by myeloid-derived suppressor cells and reduces tumor burden.
Rui K; Tian J; Tang X; Ma J; Xu P; Tian X; Wang Y; Xu H; Lu L; Wang S
Immunol Res; 2016 Aug; 64(4):931-9. PubMed ID: 26832917
[TBL] [Abstract][Full Text] [Related]
19. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
20. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
